BCIQ Profiles

Company Profile Report
0202 QT PDev
BioCentury & Getty Images

Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

Feb 2, 2021 | 11:54 PM GMT

Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the Phase IIb ASCEND GO-2 thyroid eye

Read the full 678 word article

How to gain access

Continue reading with a
two-week free trial.